Literature DB >> 23888053

ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice.

Guozhi Xiao1, Ting Zhang, Shibing Yu, Sojin Lee, Virtu Calabuig-Navarro, Jun Yamauchi, Steven Ringquist, H Henry Dong.   

Abstract

Hypertriglyceridemia is the most common lipid disorder in obesity and type 2 diabetes. It results from increased production and/or decreased clearance of triglyceride-rich lipoproteins. To better understand the pathophysiology of hypertriglyceridemia, we studied hepatic regulation of triglyceride metabolism by the activating transcription factor 4 (ATF4), a member of the basic leucine zipper-containing protein subfamily. We determined the effect of ATF4 on hepatic lipid metabolism in Atf4(-/-) mice fed regular chow or provided with free access to fructose drinking water. ATF4 depletion preferentially attenuated hepatic lipogenesis without affecting hepatic triglyceride production and fatty acid oxidation. This effect prevented excessive fat accumulation in the liver of Atf4(-/-) mice, when compared with wild-type littermates. To gain insight into the underlying mechanism, we showed that ATF4 depletion resulted in a significant reduction in hepatic expression of peroxisome proliferator-activated receptor-γ, a nuclear receptor that acts to promote lipogenesis in the liver. This effect was accompanied by a significant reduction in hepatic expression of sterol regulatory element-binding protein 1c (SREBP-1c), acetyl-CoA carboxylase, and fatty-acid synthase, three key functions in the lipogenic pathway in Atf4(-/-) mice. Of particular significance, we found that Atf4(-/-) mice, as opposed to wild-type littermates, were protected against the development of steatosis and hypertriglyceridemia in response to high fructose feeding. These data demonstrate that ATF4 plays a critical role in regulating hepatic lipid metabolism in response to nutritional cues.

Entities:  

Keywords:  ATF4; Diabetes; Lipid Metabolism; Liver; Metabolism; Mice; Obesity; Triglyceride

Mesh:

Substances:

Year:  2013        PMID: 23888053      PMCID: PMC3757199          DOI: 10.1074/jbc.M113.470526

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

Review 1.  Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins.

Authors:  Edward A Fisher; Henry N Ginsberg
Journal:  J Biol Chem       Date:  2002-03-21       Impact factor: 5.157

2.  ATF4 is a mediator of the nutrient-sensing response pathway that activates the human asparagine synthetase gene.

Authors:  Fai Siu; Perry J Bain; Rene LeBlanc-Chaffin; Hong Chen; Michael S Kilberg
Journal:  J Biol Chem       Date:  2002-04-17       Impact factor: 5.157

3.  Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study.

Authors:  J M Bard; M A Charles; I Juhan-Vague; P Vague; P André; M Safar; J C Fruchart; E Eschwege
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-03       Impact factor: 8.311

4.  Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus.

Authors:  R Rahimian; E Masih-Khan; M Lo; C van Breemen; B M McManus; G P Dubé
Journal:  Mol Cell Biochem       Date:  2001-08       Impact factor: 3.396

Review 5.  Diabetic dyslipidaemia.

Authors:  D J Betteridge
Journal:  Diabetes Obes Metab       Date:  2000-03       Impact factor: 6.577

6.  Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.

Authors:  M Bedoucha; E Atzpodien; U A Boelsterli
Journal:  J Hepatol       Date:  2001-07       Impact factor: 25.083

7.  Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.

Authors:  R A Memon; L H Tecott; K Nonogaki; A Beigneux; A H Moser; C Grunfeld; K R Feingold
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

8.  Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.

Authors:  Kimihiko Matsusue; Martin Haluzik; Gilles Lambert; Sun-Hee Yim; Oksana Gavrilova; Jerrold M Ward; Bryan Brewer; Marc L Reitman; Frank J Gonzalez
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  ApoC-III gene polymorphisms and risk of coronary artery disease.

Authors:  Oliviero Olivieri; Chiara Stranieri; Antonella Bassi; Barbara Zaia; Domenico Girelli; Francesca Pizzolo; Elisabetta Trabetti; Suzanne Cheng; Michael A Grow; Pier Franco Pignatti; Roberto Corrocher
Journal:  J Lipid Res       Date:  2002-09       Impact factor: 5.922

10.  Central activating transcription factor 4 (ATF4) regulates hepatic insulin resistance in mice via S6K1 signaling and the vagus nerve.

Authors:  Qian Zhang; Junjie Yu; Bin Liu; Ziquan Lv; Tingting Xia; Fei Xiao; Shanghai Chen; Feifan Guo
Journal:  Diabetes       Date:  2013-03-01       Impact factor: 9.461

View more
  39 in total

1.  [Effects of sera of rats fed with Huganqingzhi tablets on endoplasmic reticulum stress in a HepG2 cell model of nonalcoholic fatty liver disease].

Authors:  Miaoting Yang; Zhijuan Chen; Chunxin Xiao; Waijiao Tang; Beijie Zhou
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  Human CHAC1 Protein Degrades Glutathione, and mRNA Induction Is Regulated by the Transcription Factors ATF4 and ATF3 and a Bipartite ATF/CRE Regulatory Element.

Authors:  Rebecca R Crawford; Eugenia T Prescott; Charity F Sylvester; Ashlee N Higdon; Jixiu Shan; Michael S Kilberg; Imran N Mungrue
Journal:  J Biol Chem       Date:  2015-04-30       Impact factor: 5.157

3.  Liver-specific Gene Inactivation of the Transcription Factor ATF4 Alleviates Alcoholic Liver Steatosis in Mice.

Authors:  Kai Li; Yuzhong Xiao; Junjie Yu; Tingting Xia; Bin Liu; Yajie Guo; Jiali Deng; Shanghai Chen; Chunxia Wang; Feifan Guo
Journal:  J Biol Chem       Date:  2016-07-12       Impact factor: 5.157

4.  Identification of five genes in endoplasmic reticulum (ER) stress-apoptosis pathways in yellow catfish Pelteobagrus fulvidraco and their transcriptional responses to dietary lipid levels.

Authors:  Dian-Guang Zhang; Jie Cheng; Zhi-Peng Tai; Zhi Luo
Journal:  Fish Physiol Biochem       Date:  2019-03-07       Impact factor: 2.794

Review 5.  The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease.

Authors:  Myeong Jun Song; Harmeet Malhi
Journal:  Pharmacol Ther       Date:  2019-08-13       Impact factor: 12.310

Review 6.  Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives.

Authors:  Christina-Maria Flessa; Ioannis Kyrou; Narjes Nasiri-Ansari; Gregory Kaltsas; Athanasios G Papavassiliou; Eva Kassi; Harpal S Randeva
Journal:  Curr Obes Rep       Date:  2021-03-22

Review 7.  Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Xue-Qun Zhang; Cheng-Fu Xu; Chao-Hui Yu; Wei-Xing Chen; You-Ming Li
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 8.  The role of ER stress in lipid metabolism and lipotoxicity.

Authors:  Jaeseok Han; Randal J Kaufman
Journal:  J Lipid Res       Date:  2016-05-04       Impact factor: 5.922

9.  Preemptive Activation of the Integrated Stress Response Protects Mice From Diet-Induced Obesity and Insulin Resistance by Fibroblast Growth Factor 21 Induction.

Authors:  Xu Xu; Christopher Krumm; Jae-Seon So; Curtis J Bare; Corey Holman; Jesper Gromada; David E Cohen; Ann-Hwee Lee
Journal:  Hepatology       Date:  2018-11-05       Impact factor: 17.425

Review 10.  Mechanistic review of drug-induced steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2015-09-05       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.